{{Rsnum
|rsid=10120688
|Gene=CDKN2B-AS1
|Chromosome=9
|position=22056500
|Orientation=plus
|GMAF=0.4325
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CDKN2B-AS1,LOC102724137
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 26.5 | 46.9 | 26.5
| HCB | 51.8 | 41.6 | 6.6
| JPT | 46.9 | 37.2 | 15.9
| YRI | 17.0 | 51.0 | 32.0
| ASW | 17.5 | 49.1 | 33.3
| CHB | 51.8 | 41.6 | 6.6
| CHD | 37.6 | 47.7 | 14.7
| GIH | 34.7 | 45.5 | 19.8
| LWK | 14.5 | 40.0 | 45.5
| MEX | 67.2 | 22.4 | 10.3
| MKK | 7.1 | 46.8 | 46.2
| TSI | 30.4 | 51.0 | 18.6
| HapMapRevision=28
}}{{PMID Auto
|PMID=22521085
|Title=Glaucoma Risk Alleles at CDKN2B-AS1 Are Associated with Lower Intraocular Pressure, Normal-Tension Glaucoma, and Advanced Glaucoma
}}

{{PMID Auto
|PMID=20395613
|Title=Confirmation of an association of single-nucleotide polymorphism rs1333040 on 9p21 with familial and sporadic intracranial aneurysms in Japanese patients.
}}

{{PMID Auto
|PMID=21854539
|Title=Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}